Phase 2 Primary Biliary Cholangitis Trial, Recruiting (NCT05295680)

Phase 2 Primary Biliary Cholangitis Trial, Recruiting NCT05295680 Sponsor: Aparna Goel Condition: Primary Biliary Cholangitis

Printed from Voxsanity (voxsanity.com.au) — NCT05295680 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Primary Biliary Cholangitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a liver condition called primary sclerosing cholangitis (PSC), confirmed by a liver biopsy and/or medical imaging scan
If you also have a bowel condition called inflammatory bowel disease (IBD), it must be currently well-controlled and stable, with low disease activity scores, normal blood and stool test results, and you must have been on a stable treatment for at least 6 months

Who may not be able to join:

You are currently taking a type of medication called biologic therapies (medicines made from living cells, often used for immune or inflammatory conditions)
You have a known allergy to a substance called hymecromone (the treatment being studied in this trial)
You have been diagnosed with a type of bile duct cancer called cholangiocarcinoma
You are currently pregnant
You have a serious liver disease (confirm with trial site for specific details on what qualifies)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05295680

Sponsor: Aparna Goel

Phase: Phase 2

Status: Recruiting

Condition: Primary Biliary Cholangitis

More information: https://clinicaltrials.gov/study/NCT05295680

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a liver condition called primary sclerosing cholangitis (PSC), confirmed by a liver biopsy and/or medical imaging scan
If you also have a bowel condition called inflammatory bowel disease (IBD), it must be currently well-controlled and stable, with low disease activity scores, normal blood and stool test results, and you must have been on a stable treatment for at least 6 months

Who may not be able to join:

You are currently taking a type of medication called biologic therapies (medicines made from living cells, often used for immune or inflammatory conditions)
You have a known allergy to a substance called hymecromone (the treatment being studied in this trial)
You have been diagnosed with a type of bile duct cancer called cholangiocarcinoma
You are currently pregnant
You have a serious liver disease (confirm with trial site for specific details on what qualifies)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Aparna Goel

Registry

ClinicalTrials.gov

Start date

10 May 2023

Est. completion

1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in serum gamma-glutamyltransferase (GGT) levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov